Background: One out of seven individuals who have suffered a traumatic brain injury (TBI) develops a posttraumatic stress disorder (PTSD), which is often associated with neurocognitive impairment. The present study explores the impact of neurocognitive functioning after mild, moderate, and severe TBI on the course of PTSD symptoms.
Methods: The data of 671 adults admitted to hospital for a TBI was drawn from the Collaborative European Neurotrauma Effectiveness Research (CENTER-TBI) study. After six- and 12-months post-injury, participants completed the PTSD Checklist-5 (PCL-5), from which change scores were calculated. At six months, participants also completed a neurocognitive assessment including the Rey Auditory Verbal Learning Test, the Trail Making Test, and the Cambridge Neuropsychological Test Automated Battery (CANTAB). Linear regressions were performed to identify associations between cognitive functioning and PCL-5 change scores.
Results: Overall, mean PCL-5 change scores showed no clear change (-0.20 ± 9.88), but 87 improved and 80 deteriorated by a change score of 10 or more. CANTAB Rapid Visual Information Processing scores were significantly associated with PCL-5 change scores.
Conclusions: Strong sustained attention was associated with improvement in PTSD symptoms. Assessing cognitive performance may help identify individuals at risk of developing (persisting) PTSD post-TBI and offer opportunities for informing treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584567 | PMC |
| http://dx.doi.org/10.3390/jcm10215109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: The study's aim was to determine co-occurrence of psychopathological symptoms and personality predispositions in post-traumatic stress disorder (PTSD) and its dimensions several months after hospitalisation of patients with severe COVID-19 during the 2nd and 3rd waves of the epidemic.
Methods: At 7-8 months after admission, 138 patients completed the PCL-5 and TIPI questionnaires, as well as the HADS and AIS scales. Correlation analysis and stepwise multiple regression analysis were used in the models.
Using network analysis to characterize clinical improvement during cognitive processing therapy.
Behav Res Ther
December 2024
Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.
Objective: Cross-sectional network studies find mixed results regarding changes in network structure as a response to treatment across disorders. This study characterized improvement in mental health following Cognitive Processing Therapy (CPT) for PTSD in veterans from the perspective of network psychometrics and explored how cross-sectional networks inform our understanding of PTSD recovery.
Methods: Veterans with PTSD participated in CPT-based intensive treatment programs (ITPs), offered in two-week (N = 635) or three-week (N = 457) formats.
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.
Psychopharmacology (Berl)
January 2025
GGZ Research, Academic Center for Trauma and Personality, Amsterdam, Netherlands.
Rationale: Psychedelic-assisted therapy is increasingly applied within mental health treatment.
Objectives: This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree of mystical type experiences during the dosing, as well as emotional breakthrough and personal growth after the program.
Methods: At baseline, 1 week and 3 months after the psilocybin program participants completed the Generalized Anxiety Disorder Assessment (GAD-7), Patient Health Questionnaire (PHQ-9), PTSD Checklist for DSM-5 (PCL-5) and NEO Five-Factor Inventory-3 (NEO-FFI-3).
Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.
Eur Neuropsychopharmacol
December 2024
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, Toronto Western Hospital - University Health Network, Toronto, ON, Canada; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address:
Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients from the Canadian Rapid Treatment Center of Excellence to compare the effectiveness of four ketamine infusions (0.
View Article and Find Full Text PDFPsilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.
JAMA Netw Open
December 2024
Fred Hutchinson Cancer Center, Seattle, Washington.
Importance: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-19 pandemic includes burnout, depression, and posttraumatic stress disorder (PTSD).
Objective: To investigate whether psilocybin therapy could improve symptoms of depression, burnout, and PTSD in US clinicians who developed these symptoms from frontline clinical work during the pandemic.
Design, Setting, And Participants: This double-blind randomized clinical trial enrolled participants from February to December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!